B-cell lymphoma-related hemophagocytic syndrome
Conditions
Interventions
Zuberitamab group:Zuberitamab in combination with polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Meets the diagnostic criteria for HLH-2004; 2. Histologically confirmed mature B-cell lymphoma with positive CD20 expression by immunohistochemistry; 3. Age >= 18 years old; 4. Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study period and for >= 12 months after the last dose; pregnant and lactating women are excluded; all male subjects must use contraception during the study period and for >= 3 months after the last dose; 5. Able to provide informed consent and comply with study requirements.
Exclusion criteria
Exclusion criteria: 1. Patients with hypersensitivity to Zuberitamab, any drug excipients, or murine proteins; 2. Patients with cardiac disease classified as New York Heart Association (NYHA) Class II or above; 3. Patients with HIV infection; 4. Patients with severe renal impairment (glomerular filtration rate 20); 6. Uncontrolled infection (including pulmonary infection, intestinal infection, etc.); 7. Patients with severe psychiatric disorders; 8. Patients concurrently participating in other clinical studies; 9. Patients deemed unsuitable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Remission Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Countries
China
Contacts
Public ContactXue Kai
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed